


PRINCESS²

ULTRAFAST HYPOTHERMIA IN CARDIAC ARREST


Per Nordberg, PI - Fia Börjesson, Study coordinator - Thomas Hermansson, Head of training

THE FACTS



ORIGINAL ARTICLE

Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest




COOLING METHOD

TRANSNASAL EVAPORATIVE COOLING

- **Primarily brain cooling**
- **Easy to use, early initiation**
- **Non-invasive**
- **Continuous cooling**
- **No volume load**






The RhinoChill™ IntraNasal Cooling System
can be easily deployed during resuscitation efforts.

RhinoChill™ IntraNasal
Cooling System

PRINCESS

JAMA 2019



677 PATIENTS

343 INTERVENTION vs 334 CONTROLS

138 INTERVENTION vs 135 CONTROLS

Inclusion criteria

Bystander witnessed OHCA

Age ≥ 18 years

Predefined subgroup
Ventricular fibrillation

Exclusion criteria


Age ≥ 80 years

Obvious non-cardiac cause


ROSC prior to randomization

EMS time > 15 minutes


CPC 1-2 at 90 days



PRIMARY OUTCOME



COMPLETE RECOVERY






PRINCE AND PRINCESS TRIALS, 858 PATIENTS

**Pooled analysis
by initial rhythm**

KAPLAN MEIER CURVE

SURVIVAL WITH CPC 1-2 AT 90 DAYS

SHOCKABLE RHYTHMS



36.4%, intervention


25.6%, control

Control -	160	43	41	41
Intervention -	154	58	57	56

KAPLAN MEIER CURVE

SURVIVAL WITH CPC 1-2 AT 90 DAYS

NON-SHOCKABLE RHYTHMS



4.4%, intervention

4.9%, control

Control -	264	13	13	13
Intervention -	249	11	11	11

HYPOTHESIS:

Ultrafast hypothermia in cardiac arrest with shockable rhythms increase survival with complete recovery compared to normothermia.

DESIGN:

Multicenter RCT


1000 patients with VF

Intra-arrest and early post-ROSC

STUDY SITES



POPULATION



Inclusion criteria

OHCA with shockable rhythms


Age ≥ 18 years

Within 20 min from EMS arrival

Exclusion criteria

Age ≥ 80 years

Obvious non-cardiac cause



**OUT-OF-HOSPITAL
CARDIAC ARRESTS**

INTERVENTION


CONTROL

PREHOSP COOLING

STANDARD CARE

COOLING AT ICU

NORMOTHERMIA



For the EMS

- Equipment in a complete bag including oxygen cylinder
- Randomize after airway (SGA or intubation), within 20 minutes from EMS arrival on scene
- Randomization envelopes with patient study criteria (i.e. adult VF-patients) are in the bag
- Initiate cooling immediately if allocated to intervention (control group standard care)
- During transfer, use oxygen supply in the ambulance
- At ED arrival, switch to hospital RhinoChill Device
- Digital CRF with the most important variables

AT THE SCENE OF THE CARDIAC ARREST

Manage the airway (SEA or intubation) before placing nasal catheters.

Start the RhinoChill medium flow (40 liters/minute).

Use the oxygen in the ambulance during transport.

Inclusion and exclusion criteria

Patienten är lämplig för inklusion om "JA" till följande	
• ≥ 18 års ålder	
• Initialt defibrillerbar rytm	
• Medvetslös (GCS ≤ 8)	
• Inklusion inom 20 min från ambulansens ankomst (första enheten)	
<i>Inklusiorkan göras både intra-arrest och efter ROSC</i>	

Patienten är <i>INTE</i> lämplig för inklusion om "JA" till en eller fler av följande;	
• ≥ 80 års ålder	
• Uppenbart icke-kardiellt hjärtstopp	
• Uppenbart redan hypoterm	
• Uppenbart hinder att placera intranasal kateter (ex intranasal obstruktion)	
• Behandlingsbegränsningar (tex EJ HLR)	
• Känd terminal sjukdom	
• Graviditet	


PRINCESS²

OFFICIAL WEBSITE OF THE PRINCESS

Randomized to:

Center:

Registration number:



Interval

Stock

229



INTERVENTION

ACLS and Cooling at the scene of the arrest.

Standardized post-resuscitation protocol

- Hypothermia to 33°C for 24 hours
- Fever control for 72 hours
- Standardized prognostication

CONTROL

ACLS at the scene of the arrest

Standardized post-resuscitation protocol

- Fever control for 72 hours
- Standardized prognostication

OUTCOME

Primary Outcome measure:

- Survival with complete neurologic function at 90 days defined as mRs 0-1.

Main secondary outcomes:

- Survival at hospital discharge
- Survival at 90 days.
- mRs 0-3 at 90 days

TIME LINE

- Study start Q1 in Sweden, Austria, Germany, Slovenia
- Assessment of sites (ongoing), goal 20-25 sites
- Expected full inclusion rate Q3-4 2024

Support for next step

Website with study documents (ethical approval, consent forms etc) and instruction film:

www.princess2.org

per.nordberg@ki.se

the Staff

Princess 2 - trial



international steering committee

 Principal Investigator
Per Nordberg, MD, PhD

 Hans-Jörg Busch – MD, PhD

 Michael Holzer – MD, PhD

 Graham Nichols – MD, PhD

 Jacob Hollenberg – MD, PhD

 Sune Forsberg – MD, PhD

 Fabio Taccone, MD, PhD

 Peter Radsel, MD, PhD

 Giuseppe Ristagno, MD, PhD


 Esteban Lopez de Sa Areses, MD, PhD

operative trial team



operative trial team

trainings and logistics

inhospital	prehospital
emelie dillenbeck	anders bäckman
akil awad	thomas hermansson
anna-sofia hallberg börjesson	

operative trial team

database and eCRF – support

martin jonsson
emelie dillenbeck
anna-sofia hallberg börjesson

meetings, startup-, monitoring visits,
trial documents, assistance

anna-sofia hallberg börjesson



Thank You

www.princess2.org

trial@princess2.org



**AT THE SCENE OF
THE CARDIAC ARREST**

Patients with shockable rhythms can be included.

Randomize as soon as possible, preferably intra-arrest.